Product Center
The launch ceremony of the four valent influenza virus subunit vaccine Huierkangxin was successfully held!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-26
- Views:
(Summary description)On September 25th, the inaugural ceremony of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
The launch ceremony of the four valent influenza virus subunit vaccine Huierkangxin was successfully held!
(Summary description)On September 25th, the inaugural ceremony of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-26 10:00
- Views:
On September 25th, the inaugural ceremony of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
At the inaugural ceremony, Mr. An Youcai, Chairman and General Manager, reviewed the eight years of hard work, affirmed his achievements, and looked forward to the future. He proposed that only through innovation can we go far, and we must firmly adhere to the five-year strategic goals, forge ahead, and jointly build a defense line for human health!
The official launch of Huier Kangxin will bring society more advanced, safer, and effective choices for influenza vaccination, reduce hesitation in vaccination, further improve the influenza vaccination rate, and assist in China's influenza prevention and control!
Relevant information
-
Influenza virus subunit vaccine (adjuvant) IND application approvedRecently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) jointly applied for a Class I new drug "Influenza Virus Subunit Vaccine (Adjuvant)" IND application, which has been approved by the Drug Evaluation Center (CDE) of the China National Medical Products Administration. The approval of this vaccine marks the completion of the full coverage of the company's subunit influenza vaccine product pipeline for trivalent and quadrivalent influenza virus subunit vaccines, providing the most accurate selection for different age groups and different demand groups. - The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
- Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
